JEIL PHARMA HOLDINGS INC. Logo

JEIL PHARMA HOLDINGS INC.

Develops and distributes APIs, generics, and modified drugs, specializing in injections.

002620 | KO

Overview

Corporate Details

ISIN(s):
KR7002620003
LEI:
Country:
South Korea
Address:
서울특별시 서초구 사평대로 343, 서초구
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Jeil Pharma Holdings Inc. is a holding company that operates in the pharmaceutical industry. Through its subsidiaries, primarily Jeil Pharmaceutical Co., Ltd. (founded in 1959), the company manufactures and distributes a wide range of pharmaceutical products. Its business encompasses the production of active pharmaceutical ingredients (APIs), generic drugs, and incrementally modified drugs. The company's portfolio includes treatments across various therapeutic areas such as analgesic anti-inflammatories, antibiotics, anticoagulants, anti-diabetics, and gastrointestinal medicines. Jeil focuses on developing new synthetic processes and high-value products, with a specialization in injection medicines.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.5 MB
2025-05-29 00:00
Governance Information
기업지배구조보고서공시
Korean 923.3 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.7 MB
2025-03-25 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 20.7 KB
2025-03-17 00:00
Audit Report / Information
감사보고서제출
Korean 21.4 KB
2025-03-17 00:00
Annual Report
사업보고서 (2024.12)
Korean 2.0 MB
2025-03-10 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 987.3 KB
2025-03-05 00:00
Notice of Dividend Amount
현금ㆍ현물배당결정
Korean 9.1 KB
2025-03-05 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 8.6 KB
2025-02-24 00:00
Earnings Release
매출액또는손익구조30%(대규모법인은15%)이상변경
Korean 14.3 KB
2024-11-14 00:00
Quarterly Report
분기보고서 (2024.09)
Korean 1.5 MB
2024-09-23 00:00
Governance Information
[기재정정]기업지배구조보고서공시
Korean 847.3 KB
2024-08-28 00:00
Interim Report
[기재정정]반기보고서 (2024.06)
Korean 1.4 MB
2024-08-14 00:00
Interim Report
반기보고서 (2024.06)
Korean 1.4 MB
2024-05-30 00:00
Governance Information
기업지배구조보고서공시
Korean 844.4 KB

Automate Your Workflow. Get a real-time feed of all JEIL PHARMA HOLDINGS INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for JEIL PHARMA HOLDINGS INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for JEIL PHARMA HOLDINGS INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Genmab Logo
Creates and develops antibody therapeutics for the treatment of cancer and serious diseases.
Denmark
GMAB
GENOLUTION INC. Logo
Develops molecular diagnostic and RNAi solutions for genetic testing and life sciences research.
South Korea
225220
Genome&Company Logo
Clinical-stage biopharma developing cancer therapies using microbiome, immune inhibitors, and ADCs.
South Korea
314130
Develops molecular diagnostics using DNA methylation biomarkers for early cancer detection.
South Korea
228760
Genomtec S.A. Logo
Develops a mobile platform for rapid, precise genetic diagnostics at the point-of-care.
Poland
GMT
GENOTECH CORP. Logo
A biotech firm offering gene synthesis, genome analysis, and biopharmaceutical products globally.
South Korea
066830
Genprex, Inc. Logo
A clinical-stage firm developing non-viral gene therapies for cancer and diabetes.
United States of America
GNPX
Gentian Diagnostics ASA Logo
Develops & manufactures IVD immunoassays for human & veterinary disease diagnostics.
Norway
GENT
GERON CORP Logo
Commercializes an approved, first-in-class telomerase inhibitor for blood cancers.
United States of America
GERN
GH Research PLC Logo
Clinical-stage biopharma developing mebufotenin therapies for psychiatric disorders.
United States of America
GHRS

Talk to a Data Expert

Have a question? We'll get back to you promptly.